scanX
Home
Ajanta Pharma

Ajanta Pharma

2,565.40
+95.25
(3.86%)
search
Market Cap
32,044.95 Cr
EPS
64.82
PE Ratio
34.33
Dividend Yield
2.09 %
Industry
Healthcare
52 Week High
3,485.00
52 Week Low
2,051.60
PB Ratio
8.38
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.00 %
+80.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell+20.00 %
+20.00 %

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
Divis Laboratories
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
Cipla
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
Torrent Pharmaceuticals
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
Mankind Pharma
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
Dr Reddys Laboratories
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
Lupin
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
Zydus Life Science
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
Abbott
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
Aurobindo Pharma
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Growth Rate
Revenue Growth
11.77 %
Net Income Growth
38.81 %
Cash Flow Change
-0.89 %
ROE
31.87 %
ROCE
41.19 %
EBITDA Margin (Avg.)
27.48 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
369
394
445
472
429
481
523
552
483
478
550
602
536
519
559
490
517
620
656
666
739
681
721
754
759
781
914
862
900
984
978
1,007
919
1,053
1,050
1,119
1,090
1,171
1,206
1,177
Expenses
248
269
288
313
289
310
343
356
319
346
357
390
391
354
378
378
388
444
466
466
533
445
442
507
497
528
622
598
664
729
742
802
733
750
738
791
776
815
876
825
EBITDA
121
125
157
159
140
171
179
197
163
132
193
213
145
166
182
112
129
176
190
200
206
236
279
247
262
253
292
264
236
255
237
205
186
303
312
328
314
357
331
351
Operating Profit %
32 %
30 %
34 %
33 %
32 %
35 %
33 %
33 %
33 %
27 %
34 %
34 %
26 %
31 %
31 %
22 %
25 %
28 %
27 %
29 %
22 %
33 %
38 %
32 %
34 %
29 %
30 %
29 %
24 %
23 %
21 %
17 %
17 %
27 %
28 %
28 %
26 %
29 %
26 %
28 %
Depreciation
13
10
11
12
11
13
14
15
19
13
15
15
17
17
18
19
19
23
23
24
26
28
28
29
31
31
32
32
31
32
33
33
33
33
34
34
34
34
34
36
Interest
2
1
1
2
1
0
0
0
0
0
0
0
0
0
0
0
1
2
5
2
4
2
2
3
3
2
0
1
7
1
1
3
1
1
2
3
2
1
6
8
Profit Before Tax
115
119
148
153
134
158
165
181
144
119
178
198
128
148
164
93
109
151
162
175
176
207
249
216
229
220
260
231
198
222
203
168
152
269
276
291
278
322
290
307
Tax
41
33
45
39
25
39
35
38
30
24
46
50
34
43
38
26
20
37
45
68
47
59
79
39
70
47
65
39
47
47
46
34
30
61
81
81
75
76
74
75
Net Profit
74
86
103
114
109
120
131
143
114
95
132
148
95
106
125
67
89
115
116
108
129
148
170
177
159
174
196
192
151
175
157
135
122
208
195
210
203
246
217
233
EPS in ₹
8.43
9.78
11.76
12.95
12.38
13.58
14.85
16.19
12.96
10.77
14.99
16.76
10.74
12.02
14.25
7.60
10.10
13.14
13.34
12.33
14.80
16.93
19.51
20.41
18.40
20.08
15.10
22.16
17.70
13.63
12.22
10.50
9.54
16.53
15.51
16.68
16.10
19.54
17.27
18.60
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,146
1,481
1,848
2,449
2,696
3,319
3,779
4,056
4,679
4,638
Fixed Assets
288
452
589
1,053
1,178
1,472
1,541
1,512
1,496
1,479
Current Assets
633
764
851
1,224
1,180
1,642
2,028
2,265
2,834
2,731
Capital Work in Progress
170
240
339
61
262
132
108
153
210
257
Investments
20
66
182
190
78
79
176
147
535
349
Other Assets
669
724
738
1,145
1,179
1,635
1,954
2,244
2,438
2,554
Total Liabilities
1,146
1,481
1,848
2,449
2,696
3,319
3,779
4,056
4,679
4,638
Current Liabilities
250
272
247
346
378
606
649
647
1,139
896
Non Current Liabilities
56
38
33
61
73
114
135
144
152
175
Total Equity
841
1,172
1,568
2,041
2,245
2,599
2,996
3,264
3,388
3,567
Reserve & Surplus
823
1,154
1,550
2,024
2,228
2,581
2,978
3,247
3,363
3,542
Share Capital
18
18
18
18
18
18
17
17
25
25
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
16
-0
24
25
4
104
-24
28
124
-201
Investing Activities
-158
-209
-383
-256
-223
-224
-282
-74
-560
65
Operating Activities
279
326
609
281
375
457
576
562
792
785
Financing Activities
-105
-117
-202
-0
-148
-129
-318
-460
-108
-1,051
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Apr 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
70.34 %
70.34 %
70.34 %
70.34 %
70.48 %
70.48 %
70.48 %
66.11 %
66.11 %
66.21 %
66.21 %
66.21 %
66.21 %
66.21 %
66.27 %
66.26 %
66.26 %
66.26 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.54 %
8.36 %
9.11 %
9.26 %
8.86 %
DIIs
10.88 %
11.04 %
11.51 %
11.55 %
11.61 %
11.92 %
12.15 %
15.82 %
15.98 %
16.02 %
14.70 %
14.91 %
16.01 %
17.49 %
17.41 %
17.10 %
17.02 %
17.48 %
Government
0.76 %
0.43 %
0.43 %
0.45 %
0.45 %
0.45 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
7.64 %
7.42 %
7.45 %
7.29 %
7.33 %
7.45 %
7.31 %
7.17 %
7.10 %
6.94 %
6.92 %
7.21 %
7.07 %
6.91 %
7.08 %
6.71 %
6.67 %
6.63 %
Others
10.37 %
10.76 %
10.26 %
10.37 %
10.13 %
9.70 %
10.06 %
10.90 %
10.82 %
10.82 %
12.16 %
11.67 %
10.70 %
0.84 %
0.86 %
0.80 %
0.79 %
0.76 %
No of Share Holders
44,881
45,664
52,263
57,897
60,759
64,445
62,048
59,798
83,549
56,939
54,874
56,277
54,351
55,488
70,316
64,315
66,896
70,827

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 8 13 0.00 9 13 9.5 9.5 7 51 0.00
Dividend Yield (%) 0.68 1.4 0.00 0.99 1.09 0.79 0.79 0.31 1.94 0.00

Corporate Action

Announcements

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Apr 03, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Apr 03, 2025
Closure of Trading WindowMar 27, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 24, 2025
Intimation For Capacity Addition Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 20, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 11, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 11, 2025
Participation In Investor ConferenceFeb 20, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Feb 14, 2025
Participation In Investor ConferenceFeb 07, 2025
Integrated Filing (Financial)Feb 05, 2025
Grant Of Stock Appreciation RightsFeb 05, 2025
Rumour verification - Regulation 30(11)Feb 04, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Cancellation Of Employee Stock OptionsJan 30, 2025
Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024 Pursuant To Reg 33 Of SEBI (LODR)Jan 30, 2025
Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St December 2024.Jan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 17, 2025
Board Meeting Intimation for Approving Unaudited Financial Results For The Quarter Ended 31St December 2024.Jan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Dec 27, 2024
Closure of Trading WindowDec 27, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 09, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 30, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 29, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 28, 2024
Corporate Action- Fixation Of Record Date For Ist Interim Dividend For FY 25.Oct 28, 2024
Corporate Action-Board approves DividendOct 28, 2024
Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Half Year Ended 30.09.2024.Oct 28, 2024
Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter And Half Year Ended 30.09.2024Oct 28, 2024
Intimation Of Record Date For The Purpose Of DividendOct 23, 2024
Corporate Action-Board to consider DividendOct 23, 2024
Update On Board MeetingOct 23, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2024
Board Meeting Intimation for Board Meeting Scheduled To Be Held On Monday 28Th October 2024.Oct 17, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Closure of Trading WindowSep 26, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011Sep 25, 2024
Participation In Investor ConferenceSep 18, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Sep 11, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Sep 10, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 23, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Aug 21, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Aug 21, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Aug 21, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Aug 13, 2024

Technical Indicators

RSI(14)
Neutral
48.42
ATR(14)
Less Volatile
114.77
STOCH(9,6)
Neutral
27.56
STOCH RSI(14)
Neutral
40.28
MACD(12,26)
Bearish
-13.57
ADX(14)
Weak Trend
19.45
UO(9)
Bearish
45.11
ROC(12)
Downtrend And Accelerating
-7.32
WillR(14)
Neutral
-57.04
Bearish
4
Neutral
5
Bullish
0

About Ajanta Pharma

Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the US FDA. Ajanta Pharma has a strong research and development center in Mumbai with over 750 scientists. The company's business includes branded generics in emerging markets, generics in the USA, and institutional sales. Established in 1973, Ajanta Pharma has expanded its operations over the years, entering new markets and launching various products. The company is publicly listed on the BSE and NSE, and has undertaken several expansion projects and buybacks in recent years.
Listing Date
05 Jun, 2000(24 Years, 41 days)
Website
https://www.ajantapharma.com
Chairperson NameMannalal B Agrawal
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Price & Volume Screeners
Technical Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.